- ISIN
- VGG111961055
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 23, 2022
Highlights
- Market Cap
- $2.18B
- Enterprise Value
- $2.19B
- EPS (TTM)
- -$5.44
- Gross Profit (TTM)
- -$2.07M
- EBITDA (TTM)
- -$654.90M
- Year Range
- $7.48 - $18.57
- Target Price
- $21.29
- ROA (TTM)
- -138.87%
- ROE (TTM)
- -500.14%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BHVN Performance Chart
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is up 30.9% since the beginning of the year. At $15 per share, BHVN is trading 20.4% below its 52-week high of $19.
Loading charts...
Returns By Period
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) has returned 30.91% so far this year and 2.21% over the past 12 months.
Biohaven Pharmaceutical Holding Company Ltd.
- 1D
- -4.65%
- 1M
- 56.40%
- YTD
- 30.91%
- 6M
- 40.76%
- 1Y
- 2.21%
- 3Y*
- -13.95%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
BHVN Monthly Returns History
Based on dividend-adjusted daily data since Sep 23, 2022, BHVN's average daily return is +0.24%, while the average monthly return is +5.34%. At this rate, an investment would double in approximately 1.1 years.
Historically, 52% of months were positive and 48% were negative. The best month was Oct 2022 with a return of +163.0%, while the worst month was Nov 2025 at -41.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.
On a daily basis, BHVN closed higher 48% of trading days. The best single day was Oct 5, 2022 with a return of +47.6%, while the worst single day was Nov 5, 2025 at -40.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.78% | -2.62% | -26.56% | 13.36% | 14.81% | 34.24% | 30.91% | ||||||
| 2025 | 2.41% | -2.80% | -35.34% | -7.99% | -33.05% | -4.73% | 7.02% | 1.92% | -2.47% | 14.59% | -41.69% | 12.56% | -69.77% |
| 2024 | 3.93% | 8.23% | 13.61% | -29.05% | -9.54% | -1.11% | 13.31% | 0.18% | 26.83% | -0.42% | -7.54% | -18.82% | -12.73% |
| 2023 | 37.54% | -19.96% | -10.60% | -4.25% | 33.87% | 36.61% | -16.89% | -8.00% | 42.21% | 1.92% | 25.69% | 28.45% | 208.36% |
| 2022 | 5.00% | 163.02% | -4.53% | -12.26% | 131.33% |
Benchmark Metrics
Biohaven Pharmaceutical Holding Company Ltd. has an annualized alpha of 33.12%, beta of 1.60, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since September 23, 2022.
- This stock captured 202.25% of S&P 500 Index gains and 181.53% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 33.12%
- Beta
- 1.60
- R²
- 0.09
- Upside Capture
- 202.25%
- Downside Capture
- 181.53%
Return for Risk
Risk / Return Rank
BHVN ranks 46 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BHVN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.76 | ||
| Sortino ratioReturn per unit of downside risk | -1.69 | ||
| Omega ratioGain probability vs. loss probability | 1.10 | 1.32 | -0.23 |
| Calmar ratioReturn relative to maximum drawdown | 0.04 | 2.46 | -2.42 |
| Martin ratioReturn relative to average drawdown | 0.06 | 10.92 | -10.85 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Biohaven Pharmaceutical Holding Company Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Biohaven Pharmaceutical Holding Company Ltd. was 86.96%, occurring on Nov 10, 2025. The portfolio has not yet recovered.
The current Biohaven Pharmaceutical Holding Company Ltd. drawdown is 75.26%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -86.96%Nov 2025 | 1y 8mo | — | 2y 3moMar 2024 - now |
2023 bear market2023 | -35.90%Sep 2023 | 2mo 6d | 19d | 2mo 25dJul 2023 - Oct 2023 |
2023 bear market2023 | -34.17%Apr 2023 | 2mo 16d | 1mo 22d | 4mo 8dJan 2023 - Jun 2023 |
Bear market2022 | -25.44%Sep 2022 | 3d | 5d | 8dSep 2022 - Oct 2022 |
Bear market2022 | -24.76%Dec 2022 | 1mo 25d | 15d | 2mo 10dNov 2022 - Jan 2023 |
Drawdown Indicators
| BHVN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.96% | -56.78% | -30.18% |
Max Drawdown (1Y)Largest decline over 1 year | -56.99% | -9.10% | -47.89% |
Max Drawdown (3Y)Largest decline over 3 years | -86.96% | -18.90% | -68.06% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -75.26% | -3.21% | -72.05% |
Average DrawdownAverage peak-to-trough decline | -39.00% | -10.71% | -28.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.23% | 2.04% | +32.19% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Biohaven Pharmaceutical Holding Company Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Biohaven Pharmaceutical Holding Company Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BHVN in comparison with other companies in the Biotechnology industry. Currently, BHVN has a P/B value of 16.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BHVN
Add Biohaven Pharmaceutical Holding Company Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BHVN